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Abstract
Background: Microglia in the central nervous system (CNS) were reported to play crucial role in neurodegeneration.
Previous studies showed that P2Y6 receptor (P2Y6R) mainly contributed to microglia activation and phagocytosis in
CNS. However, the level of P2Y6R in Parkinson’s disease (PD) patients is unclear. Therefore, we measured the
level of P2Y6R in PD patients and speculated whether it could be a potential biomarker for PD. Given on the
basis that P2Y6R was higher in PD patients, we further explored the mechanisms underlying P2Y6R in the
pathogenesis of PD.
Methods: We tested the expression level of P2Y6R in the peripheral blood mononuclear cells (PBMCs) among
145 PD patients, 170 healthy controls, and 30 multiple system atrophy (MSA) patients. We also used a
lipopolysaccharide (LPS)-stimulated microglial cell culture model to investigate (i) the effects of LPS on P2Y6R
expression with western blot and RT-PCR, (ii) the effects of LPS on UDP expression using HPLC, (iii) the
effects of UDP/P2Y6R signaling on cytokine expression using western blot, RT-PCR, and ELISA, and (iv) the
signaling pathways activated by the P2Y6R involved in the neuroinflammation.
Results: Expression levels of P2Y6R in PD patients were higher than healthy controls and MSA patients. P2Y6R
could be a good biomarker of PD. P2Y6R was also upregulated in LPS-treated BV-2 cells and involved in
proinflammatory cytokine release through an autocrine loop based on LPS-triggered UDP secretion and
accelerated neuroinflammatory responses through the ERK1/2 pathway. Importantly, blocking UDP/P2Y6R
signaling could reverse these pathological processes.
Conclusions: P2Y6R may be a potential clinical biomarker of PD. Blocking P2Y6R may be a potential therapeutic
approach to the treatment of PD patients through inhibition of microglia-activated neuroinflammation.
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Background
Microglia are the major cells involved in immune func-
tion within the CNS, and accumulating evidence sug-
gests that microglia act as key players in the initiation of
various CNS diseases, including Parkinson’s disease (PD)
[1–3]. Postmortem analyses of PD patients and experi-
mental animal studies have indicated that the activation
of glial cells and increased proinflammatory factor levels
are common features in PD brains [4, 5]. A better
understanding of the mechanism of the regulation of
microglial function is crucial for developing effective
therapeutics for PD. However, the trigger for inducing
microglial release of proinflammatory mediators in PD
remains to be elucidated.
Nucleotides have been explored as inducers of brain
inflammation [6]. In the context of chronic brain inflam-
mation, neurons can release both adenine (such as ATP)
and uracil nucleotides (such as UTP and UDP) into the
extracellular space upon physiological activity and in
response to pathological stimuli and cellular damage,
which affects the motility of adjacent cells, including
microglia [7, 8]. The roles of adenine nucleotides, such
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as ATP, in inflammatory processes have been intensively
studied [9]. Nucleotide receptors are normally divided
into two subfamilies: the ionotropic receptor (P2X) fam-
ily and the metabotropic receptor (P2Y) family. The acti-
vation of P2Y receptors plays important roles in the
nervous system. The activation of P2Y1 receptor can
modulate neuronal activity and neuronal fiber outgrowth
[10, 11], and P2Y12 receptor is involved in microglial
migration driven by ATP [12]. There is evidence of a
prominent role of P2Y2 receptor in Alzheimer’s disease
pathology [13, 14].
As a member of the P2Y receptor family, the purino-
ceptor P2Y6 receptor (P2Y6R) is widely distributed in
various tissues, including the placenta, spleen, thymus,
small intestine, blood, heart, blood vessels, and brain
[15]. P2Y6R plays an important role in immunoinflam-
mation in the peripheral system. UDP, known to be a
specific agonist of P2Y6R, has been demonstrated to me-
diate the secretion of C-X-C motif chemokine ligand 8
(CXCL8) and macrophage inflammatory protein-3 (MIP-
3a) in monocytes and in intestinal and lung epithelial
cells [16–18]. P2Y6R is highly expressed on T cells that
infiltrate inflamed colonic tissues but is absent in T cells
of the unaffected bowel [19]. P2Y6R also participates in
toll-like receptor (TLR) 1/2-induced neutrophil migra-
tion by regulating IL-8 secretion [20]. Moreover, P2Y6R
activation potentiates proinflammatory responses in
macrophages [21]. In the CNS, a number of studies have
demonstrated that damaged neurons can release UDP,
which contributes to the microglial phagocytosis of
dying neurons [22, 23]. In addition, UDP induced the
expression of chemokines via a P2Y6R-dependent mech-
anism in brain microglia and astrocytes [24]. However,
the role of P2Y6R in the CNS, especially in microglia-
associated processes, requires further investigation, and
whether its level is abnormal in sporadic PD patients
remains to be identified.
Here, we found that P2Y6R levels were elevated in the
peripheral blood mononuclear cells (PBMCs) of PD
patients and, therefore, P2Y6R could be a potential clin-
ical biomarker of PD. UDP/P2Y6R signaling was in-
volved in the neuroinflammation mediated by microglia,
and blocking P2Y6R could be a therapeutic approach for




In our study, 145 PD patients, 170 control subjects, and
30 possible multiple system atrophy (MSA) patients were
recruited from the Department of Neurology, Ruijin
Hospital affiliated to Shanghai Jiao Tong University
School of Medicine. The clinical diagnosis of PD was
established by two independent senior movement disorder
specialists using the United Kingdom Parkinson’s Disease
Society Brain Bank clinical diagnostic criteria [25]. The
diagnosis of possible MSA was made according to the sec-
ond consensus statement on the diagnosis of MSA [26].
The clinical features of the PD patients were collected,
and PD symptoms were evaluated using the Unified
Parkinson’s Disease Rating Scale (UPDRS) and the Hoehn
and Yahr (H-Y) staging modified version. The study was
approved by the Ethics Committee of Ruijin Hospital
affiliated to Shanghai Jiao Tong University School of
Medicine, and written informed consent was obtained from
all participants. Venous whole blood samples (4–5 ml) were
collected from the individuals of the three groups on an
empty stomach in the morning and mixed thoroughly with
EDTA to prevent coagulation. Blood samples were col-
lected in tubes containing EDTA. Then, the peripheral
blood mononuclear cells (PBMCs) were lysed with 1 ml
TRIzol reagent, and the total RNA was harvested as
described by the manufacturer’s protocol. Quantitative real-
time PCR (qRT-PCR) was performed using 4 μg of total
RNA as a template for the reverse transcription reaction
using a TakaRa 1st-strand kit. Reactions were performed
according to the manufacturer’s protocol. Complementary
DNA (cDNA) synthesized from each sample was subjected
to real-time PCR assays with specific primers and a
SYBR@Premix Ex TaqTM qPCR SuperMix (Takara). The
sequences of primers were as follows: human-P2Y6R: for-
ward 5-GCT AAC TCT TGG CTC CCG AAC A-3,
reverse 5-GCG GGA CGT GCA GAT CTG GGT A-3;
GAPDH: forward 5-CGG AGT CAA CGG ATT TGG
TCG TAT-3, reverse 5-AGC CTT CTC CAT GGT GGT
GAA GAC-3. The two-step amplification protocol con-
sisted of denaturation for 30 s at 95 °C and then followed
by 40 cycles of 95 °C for 5 s and 60 °C for 60 s. This process
was performed using a ABI7500 real-time PCR machine.
The RNA quantities of target genes were calculated using
the Ct method. The Ct values of P2Y6R amplification were
normalized to those of GAPDH amplification.
Materials
Uridine-5’-diphosphate sodium (UDP), MRS2578, lipo-
polysaccharide (LPS) (Escherichia coli 011:B4), apyrase,
dimethyl sulfoxide (DMSO), and MTT were purchased
from Sigma Chemical Co. (St. Louis, MO). U0126,
SB203580, and SP600125 were obtained from Cell Signal-
ing Technology (Danvers, MA). Optim-MEM and Lipofac-
tamine 2000 were obtained from Invitrogen (Carlsbad,
CA). The small-interfering RNA (siRNA) of P2Y6R was
provided by GenePharma (Shanghai, China).
Cell culture and transfection
Primary microglia were derived from male neonatal
C57BL/6 mice (1-day old), using the “shaking off” method.
Briefly, cerebral cortices were devoid of meninges and
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blood vessels, dissected in Hank’s salt (HBSS) and trypsi-
nized with 0.25% trypsin-EDTA for 30 min at 37 °C. The
mixed glial culture was incubated in DMEM/F-12
containing 10% fetal bovine serum (FBS) and 50 U/ml
penicillin/streptomycin (PS) and seeded at 20 × 106–25 ×
106 cells per 175 cm2 flask coated with poly-L-ornithine
(Gibco). After 2 weeks of culture, flasks were shaken and
the media were collected and centrifuged at 1000 rpm for
5 min to obtain a pellet of microglia. Isolated microglia
were allowed to attach to plates for 3 to 4 h, and
unattached cells were removed by changing the medium.
Microglial cultures were determined to be 95 to 98% pure,
as assessed by staining for Iba-1.
BV-2 cells, SH-SY5Y cells, and N2a cells were rou-
tinely cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS and 100 U/ml PS.
PC 12 cells were cultured in DMEM medium supple-
mented with 5% horse serum and 5% FBS. The cells
were plated 24 h prior to transfection at a confluency of
70 to 80%. The cells were transfected with P2Y6R or
control siRNA (scramble) by using Lipofectamine 2000
according to the manufacturer’s instructions. The P2Y6R










Reverse transcription polymerase chain reaction
Cells were plated at a density of 3 × 105 cells/well in six-
well plates, as detailed above. Then, the cells were lysed
with 1 ml TRIzol, and the total RNA was harvested as de-
scribed by the manufacturer’s protocol. Reverse transcrip-
tion polymerase chain reaction (RT-PCR) was performed
using 4 μg of total RNA as a template for the reverse tran-
scription reaction using a TakaRa 1st-strand kit. The
cDNA was then used for PCR of the murine purinergic






















The PCR reaction protocol was as follows: denatur-
ation at 95 °C for 5 min; followed by 25 cycles at 95 °C
for 30 s; P2Y6R, iNOS, COX-2, IL-6, and TNF-α at 54 °
C and MIP-2 and β-actin at 58 °C for 30 s, 72 °C for
30 s, and finally, extension at 72 °C for 5 min. The PCR
products were separated by 2% agarose gel electrophor-
esis and visualized via ethidium bromide staining.
Immunofluorescence analysis
To examine the morphology change of primary micro-
glia cells, we pretreated primary microglia cells with apy-
rase (1 U/ml) and MRS2578 (5 μM) for 30 min and then
treated with LPS (100 ng/ul) for 12 h. The cells were
fixed with a fresh formaldehyde solution for 20 min
followed by permeabilization with 0.15% Triton X-100 in
PBS. Cells were then incubated overnight at 4 °C with
rabbit anti Iba1 antibody (019–19741, 1:200; Wako),
followed by washing in PBS 3 × 10 min. Then, the slices
were incubated with the Alexa Flour 594 goat anti-rabbit
IgG secondary antibody (ab150080, 1:500; Sigma) for 1 h.
Finally, cells were incubated with DAPI (10236276001,
Roche; 1:20000) for 15 min. Images were analyzed with a
phase contrast fluorescence microscope (Nickon Eclipse
E400). Experiment was performed in triplicate.
Western blotting
Cells were washed in ice-cold phosphate-buffered saline
(PBS) three times and lysed in RIPA lysis buffer (50 mM
Tris–HCl, pH 8.0; 1% NP-40; 0.5% sodium deoxycholate;
150 mM NaCl; 0.1% SDS) containing protease and phos-
phatase inhibitor cocktails (Roche) and 1 mM phenyl-
methylsulphonyl fluoride (PMSF). Protein content was
determined using a Micro-BCA Protein Assay (Thermo
Scientific). Equal amounts of protein (30 μg) were loaded
per lane and separated by 10% SDS-PAGE. The proteins
in the gels were transferred to Immobilon polyvinylidene
difluoride (PVDF) membranes (Santa Cruz, CA, USA),
and the membranes were subsequently blocked in TBST
(10 mM Tris–HCl, pH = 8.0; 150 mM NaCl; 0.05%
Tween-20) containing 5% nonfat milk. Anti-P2Y6 recep-
tor polyclonal goat antibody (sc-15217, 1:1000, Santa
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Cruz), anti-phospho-p38 (#4511); anti-phospho-ERK1/2
(#4370), and anti-phospho-JNK (#4668) antibodies; the
corresponding total-p38 (#9219), total-ERK1/2 (#9102),
and total-JNK (#9528) antibodies; and anti-cleaved
caspase-3 (#9661) antibody (Cell Signaling Technology)
were used at a dilution of 1:1000 in 3% milk/TBST. The
levels of iNOS and COX-2 were determined using anti-
iNOS antibody (sc-69190, 1:500; Santa Cruz) and anti-
COX-2 antibodies (160106, 1:800; Caymen Chemical).
All the primary antibodies were incubated overnight at
4 °C. The immunoreactive bands were visualized using
secondary antibodies conjugated to horseradish peroxid-
ase (Santa Cruz, CA, USA) and chemiluminescent detec-
tion methods (Amersham Company). To confirm equal
protein loading, the membranes were probed with anti-
bodies recognizing the cytosolic protein, β-actin (A1978,
1:2500; Sigma-Aldrich). The data shown are representative
of at least three separate experiments.
High-performance liquid chromatography
Cultured BV-2 cells were stimulated with and without
200 ng/ml LPS for 12 h, and the supernatant was then
collected and cleared of cellular debris. Detection of
UDP in the cell culture medium was determined by
reverse-phase high-performance liquid chromatography
(HPLC) (Varian Vista series) using an Agilent Zorbax
300SB-C18 column (300 A), as described previously
[27]. Cell medium samples (200 μl) or standard samples
were injected. The retention time of UDP released by
the BV-2 cells was compared with standard samples, and
the peaks were identified by comparing their retention
times with those of co-eluted standards. Quantification
was performed by integration of the peak areas and
compared with those produced by standards of known
concentrations prepared in the same solvent.
ELISA
The conditioned medium collected from the BV-2 cells
treated with LPS was evaluated for the production of
MIP-2 cytokines using ELISA (BD Biosciences, San Jose,
Calif.). ELISA was performed as recommended by the
manufacturer. The optical density of each well was
determined using a microplate reader at 405 nm, and
the amounts of cytokines were calculated from the
standard curve.
MTT assay
Cell viability was measured by an MTT assay. The neur-
onal cells (SH-SY5Y, N2a, and PC12 cells) were plated in
96-well plates. After treating with the conditioned
medium separated from the BV-2 cells for 24 h, MTT
solution at a final concentration of 5 mg/ml was added
to each well, and the plates were incubated for another
4 h. One hundred fifty microliters of DMSO was then
added to solubilize the MTT tetrazolium crystals. Finally,
the optical density was determined at 570 nm.
Statistical analysis
Analyses were conducted with t GraphPad Prism 6.0
Software. Data were expressed as the mean ± SD and were
compared by using Student’s t test between two groups
and one-way or two-way ANOVA with Bonferroni’s
correction for multiple group comparison. Pearson’s cor-
relation coefficient was chosen for correlation analyses.
Results
P2Y6R mRNA in PBMCs from PD patients is increased
compared with healthy controls and MSA patients
We measured the levels of P2Y6R messenger RNA
(mRNA) via qRT-PCR in 145 PD patients, 170 normal
controls, and 30 possible MSA patients. The subjects’
demographics are summarized in Table 1. The results
showed that the relative amount of P2Y6R mRNA in the
PD patients was significantly higher than that in the
healthy controls and MSA patients, while there was no
difference between healthy controls and MSA patients
(Fig. 1a). Furthermore, we compared the P2Y6R mRNA
levels among different age groups. P2Y6R mRNA expres-
sion levels in PD patients in the <60, 60–69, and 70–79
age groups were approximately 3.9, 2.5, and 3.5 times
greater compared to the respective age groups of the
healthy controls (Fig. 1b). However, P2Y6R mRNA expres-
sion was not significantly different between PD patients
and healthy controls older than 80. In addition, P2Y6R
mRNA expression was uncorrelated with gender, age of
disease onset, disease duration, H&Y stage, UPDRS score,
and drug administration (data not shown). We also plot-
ted the receiver operating characteristic curve (ROC
curve) according to the expression levels of P2Y6R mRNA
in both PD patients and healthy controls, with the cutoff
point being the presence of disease or not. The area under
the curve was 0.785 (95% CI = 0.734–0.838), the diagnos-
tic cutoff point was 2.15, and the diagnostic sensitivity and
specificity were 85.8 and 59.4% (Fig. 1c). Regarding PD
Table 1 The demographic characteristics of healthy controls,







Male, n (%) 95 (54.84%) 85 (60.81%) 16 (53.33%)
Age (year) 66.05 ± 9.01 66.05 ± 10.07 61.35 ± 5.91
P2Y6R 2−ΔΔCt 3.33 ± 5.71 9.88 ± 13.13 1.94 ± 2.46
Age (year)
<60 2.67 ± 3.96 (n = 48) 10.32 ± 15.04 (n = 34)
60–69 4.51 ± 8.17 (n = 62) 11.47 ± 14.19 (n = 60)
70–79 2.56 ± 3.56 (n = 42) 9.07 ± 11.22 (n = 41)
≥80 2.89 ± 2.92 (n = 18) 4.09 ± 3.78 (n = 10)
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patients and MSA patients, the area under the ROC curve
was 0.792 (95% CI = 0.778–0.959), the diagnostic cutoff
point was 2.77, and the diagnostic sensitivity and specifi-
city were 76.4 and 93.7% (Fig. 1d).
We concluded that P2Y6R expression levels are ele-
vated in PD patients and have no relationship with the
severity of disease and that P2Y6R expression might be a
stable diagnostic biomarker for PD.
LPS-activated microglia and upregulated P2Y6R
expression
We investigated the expression of P2Y6R in an acti-
vated microglia cell model. We found that incubation
of BV-2 cells with LPS increased both mRNA and pro-
tein levels of P2Y6R in a time-dependent manner, and
the highest levels of mRNA were reached at 6 h and of
protein at 12 h (Fig. 2a, c). The trends in the expression
of various inflammatory cytokines (TNF-α, iNOS, IL-6,
COX-2, and MIP-2 mRNA) were accord with the level
of P2Y6R in LPS stimulated BV-2 cells. The relative
amounts of TNF-α, iNOS, IL-6, COX-2, and MIP-2
mRNA were increased (Fig. 2c). LPS stimulation for 6
and 12 h also significantly upregulated the protein
expression levels of COX-2 and iNOS (Fig. 2b). These
findings suggest that P2Y6R expression was upregu-
lated after microglia activation.
UDP/P2Y6R signaling involved in the activation of
microglia and the production of inflammatory cytokines
Because we have demonstrated that the change in
P2Y6R expression was coordinated with inflammatory
responses, we supposed that P2Y6R might play an
important role in the LPS-induced production of inflam-
matory cytokines. UDP is known to be a specific agonist
of the P2Y6 purinergic receptor, while LPS is not the
direct agonist of P2Y6R. An obvious sine qua non of this
hypothesis is that microglia can release UDP in response
to LPS stimulation. We therefore investigated whether
LPS increased the release of extracellular UDP from
microglia. Cultured BV-2 cells were stimulated with and
without LPS, and the supernatant was then collected for
nucleotide assay based on HPLC. The amount of UDP
in the LPS-treated supernatant was significantly higher
than that in the untreated supernatant (Fig. 3a).
To examine the role of UDP/P2Y6R signaling in acti-
vated microglia-induced cytokine production, we pre-
treated the BV-2 cells with apyrase (1 U/ml) and
MRS2578 (5 μM) for 30 min. Apyrase can hydrolyze tri-
and di-phosphate nucleotides and therefore abrogate
both ATP and UDP signaling [28, 29]. MRS2578 is the
specific irreversible P2Y6R antagonist which could com-
pletely blocked P2Y6R [30, 31]. We found both apyrase
and MRS2578 reduced MIP-2 mRNA expression levels
Fig. 1 Increased P2Y6R mRNA levels in PBMCs from PD patients. a mRNA levels of P2Y6R in PBMCs of healthy controls, MSA, and PD patients.
The gene expression of P2Y6R was normalized to those of GAPDH expression. b Expression of P2Y6R mRNA among different age groups of PD
patients and control subjects. c The ROC curve of PD patients and healthy controls. d The ROC curve of PD patients and MSA patients. Data are
shown as the mean ± SD, n = 170 for healthy controls, n = 145 for PD patients, and n = 30 for MSA patiens. ***p < 0.001 vs Con, #p < 0.001 vs
multiple system atrophy (MSA)
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induced by LPS stimulation (Fig. 3b). ELISA was also
performed to quantify the impact of apyrase and
MRS2578 on MIP-2 secretion. Both apyrase and
MRS2578 significantly decreased the amount of MIP-2
released into the medium (Fig. 3c). To further validate
the role of UDP/P2Y6R signaling in activated microglia-
induced cytokine production, we turned to primary
microglia cells. The morphology of microglia cells in the
control group most frequently showed an ovoid shape.
Primary microglia cells showed significant change in
morphology after LPS treatment. Most of the LPS-
stimulated microglia cells had a large and flat shape with
other cells presenting a ramified morphology, while
pretreated primary microglia cells with apyrase and
MRS2578 can inhibit activation of the microglia as was
seen by typically resembling morphology that seen in the
control group (Fig. 3d). Confirming these results, we
found that blocking UDP/P2Y6R signaling by apyrase and
MRS2578 can reduce the inflammatory cytokines (TNF-α,
iNOS, IL-6, COX-2, and MIP-2 mRNA) production in pri-
mary microglia cells induced by LPS (Fig. 3e).
To complement the experiments with antisense oligo-
nucleotides, we also transfected BV-2 cells with P2Y6R
siRNA to knock down P2Y6R expression. The interfer-
ing efficacy of P2Y6R mRNA and protein expression was
confirmed by RT-PCR and western blot, respectively.
We chose the siRNA with the best interference effi-
ciency for further studies (Fig. 4a). Interestingly, we
found that knocking down P2Y6R reduced the protein
expression levels of iNOS and COX-2 in BV-2 cells
induced by LPS (Fig. 4b) and the inflammatory cytokine
production was also downregulated (Fig. 4c). These find-
ings suggested that inhibition of UDP/P2Y6R signaling
could partly prevent LPS-induced neuroinflammation.
Knockdown of P2Y6R can increase neuronal cell viability
and attenuate apoptosis upon exposure to conditioned
medium from LPS-stimulated BV-2 cells
To further investigate the effect of P2Y6R in microglia on
neuronal cells viability, conditioned medium from LPS-
stimulated BV-2 cells was added to different neuronal cells
(SH-SY5Y, N2a, and PC12 cells). We transfected the BV-2
cells with P2Y6R siRNA and then incubated the neuronal
cells with the supernatant from BV-2 cells treated with
LPS. The cell viability and the degree of apoptosis of the
neuronal cells were then measured based on MTT assay
and the expression of caspase-3. The results showed that
the supernatant of the LPS-treated BV-2 cells induced a de-
crease in cell viability (Fig. 5a) and an increase in caspase-3
expression levels in different neuronal cells (SH-SY5Y, N2a,
and PC12 cells) compared with the cells exposed to normal
medium (Fig. 5b). However, the decreased cell viability
(Fig. 5a) and increased caspase-3 expression (Fig. 5b) were
reversed by knocking down P2Y6R. This approach indi-
cated that P2Y6R in microglia contributed to the cell death
of neuronal cells and that knocking down P2Y6R could in-
crease cell viability and decrease apoptosis of neuronal cells
caused by the cytotoxicity of LPS-stimulated BV-2 cells.
Fig. 2 LPS-activated microglia and upregulated P2Y6R expression. a P2Y6R expression in BV-2 cells after LPS stimulation according to western
blot. b iNOS and COX-2 levels after LPS stimulation according to western blot. c Inflammatory cytokine (TNF-α, iNOS, IL-6, COX-2, and MIP-2) and
P2Y6R expression levels after LPS stimulation according to RT-PCR. The band intensity was quantified using studio lite imager and is presented
relative to the level of β-actin. Data are shown as the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs LPS 0 h
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The activation of P2Y6R is partially dependent on ERK1/2
phosphorylation
Previous studies have shown that P2Y receptor signaling
is mainly through mitogen-activated protein kinases
(MAPK) [31, 32]. To explore the mechanism by which
P2Y6R is involved in neuroinflammation process, we
investigated the levels of MAPK, including the extracel-
lular signal-regulated protein kinase (ERK1/2), p38, and
the jun-NH2-kinase (JNK). We found that P2Y6R activa-
tion induced by its specific agonist UDP caused strong
and rapid ERK1/2 phosphorylation (Fig. 6a). However,
UDP had no effect on p38 and JNK expression, whereas
LPS could activate all of the MAPK pathways (data not
shown). In addition, the involvement of MAPK pathways
in P2Y6R activation was also examined using a pharma-
cological approach. We investigated the impact of spe-
cific inhibitors for ERK1/2 (U0126), p38 (SB203580),
and JNK1/2 (SP600125) on MIP-2 mRNA expression,
COX-2 protein expression, and MIP-2 secretion. Inhib-
ition of the ERK1/2 pathway by U0126 applied 30 min
before UDP stimulation resulted in a significant decrease
in COX-2 protein and MIP-2 mRNA expression (Fig. 6b).
However, no significant inhibition of MIP-2 transcript
expression was observed in SB203580- and SP600125-
pretreated cells (data not shown). Similarly, pretreatment
of the BV-2 cells with U0126 but not SB203580 or
SP600125 before UDP stimulation abolished the release
of MIP2 measured by ELISA (Fig. 6c). These results
suggest that ERK1/2 activation is important in the
regulation of P2Y6R cytotoxicity.
Discussion
Microglia cells are well known as sensors in brain-
damaging events and are crucial to the progress of many
Fig. 3 UDP/P2Y6R signaling involved in the activation of microglia cells and the production of inflammatory cytokines. a The standard curve and
the UDP concentration in the LPS-treated and control supernatants of BV-2 cells based on HPLC. b mRNA levels of MIP-2 in LPS, LPS+Apy- and
LPS+MRS-treated BV-2 cells. c ELISA of MIP-2 secretion. d Morphological changes in LPS-stimulated and Apy/MRS pretreated primary microglia
cells. Representative immunostained images for primary microglia cells (Iba-1, red; DAPI, blue). Scale bar = 100 μm. e Representative RT-PCR
showing the expression levels of inflammatory cytokines (TNF-α, iNOS, IL-6, COX-2, and MIP-2) from LPS-stimulated primary microglia cells
pretreated with Apy/MRS. The band intensity was quantified using studio lite imager and is presented relative to the level of β-actin. Data are
shown as the mean ± SD of three independent experiments. *p < 0.05, ***p < 0.001 vs Con, #p < 0.05, ##p < 0.01, ###p < 0.001 vs LPS. Apy
(Apyrase, nucleotide hydrolase), MRS (MRS2578, P2Y6 inhibitor)
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neurodegenerative diseases [33]. It is now well recognized
that microglia functional plasticity is strictly stimuli-
dependent; however, how microglia coordinate inflamma-
tory responses is still not clearly understood. In this study,
we demonstrated for the first time that UDP/P2Y6R
signaling was actively involved in the mechanism of
neuroinflammation through an autocrine loop based on
LPS-triggered UDP secretion, which resulted in the death
of dopaminergic neurons that was partly dependent on
the phosphorylation of ERK1/2. Notably, evidence of
elevated P2Y6R levels in the PBMCs of sporadic PD
patients in China was shown, suggesting that P2Y6R may
be a potential biomarker for the diagnosis of PD.
Parkinson’s disease is a neurodegenerative disorder
that is estimated to affect more than 1% of the popula-
tion aged over 65, and there will be more than 10 mil-
lion PD patients in the world by 2030 [34]. However, to
date, the diagnosis of PD is mainly based on clinical
manifestations and is confirmed only upon autopsy.
Researchers have made many attempts to explore its
possible biomarkers and, as a result, some interesting
candidates have been identified and proven to be use-
ful alone or in combination [35]. For example, extra-
cellular α-synuclein quantification in human body
fluids, such as cerebrospinal fluid (CSF), plasma [36],
or saliva [37], has been proposed as a potential
Fig. 4 Knockdown of P2Y6R reduced the production of inflammatory cytokines. a RT-PCR and western blot analyses of P2Y6R from BV-2 cells trans-
fected with P2Y6 siRNA. b Representative western blots showing iNOS and COX-2 levels from LPS-stimulated BV-2 cells transfected with P2Y6 siRNA. c
Representative RT-PCR showing the expression levels of inflammatory cytokines (TNF-α, iNOS, IL-6, COX-2, and MIP-2) from LPS-stimulated BV-2 cells
transfected with P2Y6R siRNA. The band intensity was quantified using studio lite imager and is presented relative to the level of β-actin. Data are
shown as the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs Con, #p < 0.05, ##p < 0.01 vs LPS
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biomarker for synucleinopathies. Several studies have
reported decreased levels of homovanillic acid (HVA)
and DJ-1 in the CSF of PD patients compared with
healthy controls [38]. We investigated P2Y6R mRNA
levels in PBMCs among PD patients and age- and
gender-matched MSA patients and healthy controls.
The result showed that P2Y6R mRNA levels in PD
patients were significantly higher than in MSA
patients and healthy controls. We found that the
expression levels of P2Y6R mRNA in PD patients
Fig. 5 Knockdown of P2Y6R increased neuronal cells viability and attenuated apoptosis when exposed to the conditioned medium from LPS-
stimulated BV-2 cells. a Effects of the conditioned medium from LPS-stimulated BV-2 cells on cell viability measured by MTT assays. b Expression
of caspase-3 in neuronal cells (SH-SY5Y, N2a, and PC12 cells), exposed to the conditioned medium from LPS-stimulated BV-2 cells. Data are shown
as the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs Con, #p < 0.05, ##p < 0.01 vs LPS
Fig. 6 Activation of P2Y6R by UDP is partially dependent on ERK1/2 phosphorylation. a Representative western blots showing that ERK1/2
phosphorylation was stimulated in a time-dependent manner by UDP. b Representative western blots and RT-PCR showing that COX-2 protein
and MIP-2 mRNA levels were decreased in UDP-stimulated BV-2 cells pretreated with U0126 (ERK1/2 inhibitor). c ELISA showing that MIP-2
secretion level was decreased in UDP-stimulated BV-2 cells pretreated with U0126. SB (SB203580, P38 inhibitor), SP (SP600125, JNK1/2 inhibitor).
Data are shown as the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs Con, ##p < 0.01, ###p < 0.001 vs LPS
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were much higher than in healthy controls among the
different age groups, except for subjects over age 80,
which may be due to the fewer subjects included in
this group. Even though only 30 MSA patients were
included in this study, we also found that the P2Y6R
mRNA levels in MSA patients was significantly lower
compared with PD patients, and the diagnostic speci-
ficity was as high as 93.7%, which indicates that the
level of P2Y6R in PBMCs might be a specific bio-
marker for PD and could be used for the differential
diagnosis between PD and MSA. Further analysis
revealed that increased P2Y6R levels persisted during
the entire disease process and was not correlated with
disease severity, clinical type, or drug administration,
which indicated that P2Y6R mRNA levels cannot be
used to monitor disease progression but represent a
stable biomarker of PD. Circulating blood cells can
contact brain tissue and may provide information
reflecting the pathological environment of the PD
brain [39]. Compared with other biomarkers, P2Y6R
can be measured in the blood and therefore can be
easily acquired from patients and tested.
Elevated inflammatory cytokines are found in PD pa-
tients’ brains, and inflammation is thought to be a major
contributor to the neurodegeneration [4, 40]. In
addition, a systemic inflammatory response results in
the production of cytokines, which circulate in the blood
and communicate with neurons within the brain. It has
been demonstrated that peripheral cytokines in PBMCs
are increased in patients with PD [41]. Microglia are
known as resident macrophages in the central nervous
system. PBMCs may provide information reflecting the
immune activity of the brain in some extent. The eleva-
tion of P2Y6R expression in the PBMCs corresponded
to the inflammation of PD patients.
Upregulated P2Y6R expression was confirmed in
vitro by inducing an inflammatory stress-like insult
with LPS in BV-2 cells. The upregulation of P2Y6R
expression following inflammatory stress has been
reported in inflammatory bowel disease and in a
model of radiation-induced brain injury [19, 42]. We
found that UDP/P2Y6R signaling was also involved in
neuroinflammation. The mechanism mediating this
process is shown in Fig. 7.
We found that activated microglia could upregulate
P2Y6R expression. In addition, the change in P2Y6R ex-
pression was accompanied by the upregulation of in-
flammatory cytokines. Thus, we proposed that P2Y6R
may participate in the neuroinflammation induced by
LPS. UDP was a natural ligand of P2Y6R. It has been
demonstrated that injured or damaged neurons release
significant amounts of this nucleotide in a paracrine
manner, which acts on P2Y6R to initiate microglial
phagocytosis [22]. In this study, we found that LPS could
trigger an autocrine loop of UDP secretion in activated
microglia. The combination of UDP and P2Y6R could
then activate downstream mechanisms of the inflamma-
tory response, while either inhibition or knock down of
P2Y6R or abrogation of UDP signaling can partially
downregulate the expression of the inflammation cyto-
kines induced by LPS. We further revealed a role of
P2Y6R in the regulation of microglia function, as it
could not only initiate microglia phagocytosis but also
actively participate in the process of microglia-induced
inflammation.
With respect to the function of P2Y6R, some studies
reported UDP/P2Y6R signaling could protect astrocytes
against TNF-α induced apoptosis by preventing the acti-
vation of both caspase-3 and caspase-8 [43] and could
protect mice from vesicular stomatitis virus infection
Fig. 7 Schematic of UDP/P2Y6R signaling mediating neuroinflammation and inducing the death of neurons
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through an increase in IFN-β production [44]. However,
other study reported that activated P2Y6R may have a
toxic effect, mediating nitric oxide and iNOS production
and cause excessive astrogliosis [32]. PD is caused by the
loss of dopaminergic neurons, and neuroinflammation is
primarily involved in this pathogenesis. Our results dem-
onstrated that LPS could induce the release of many
proinflammatory factors from BV-2 and primary micro-
glia cells and that UDP/P2Y6R signaling contributed to
this process. We found that conditioned medium from
LPS-treated BV-2 cells was toxic and increased the
apoptosis of neuronal cells. However, knockdown of
P2Y6R in BV-2 cells decreased neuronal apoptosis and
increased cell viability, highlighting the concept that
activated microglia can damage neurons partly through
UDP/P2Y6R signaling. Supporting this viewpoint, we
also found decreased MIP-2 release in the conditioned
medium from BV-2 cells treated with LPS after inhib-
ition of P2Y6R. We suggest that neuroinflammation
mediated by P2Y6R might play an important role in
the pathogenesis of PD. This is the first study to ex-
plore the relationship between P2Y6R and dopamin-
ergic neurons, emphasizing the effect of inflammatory
cytokine production based on interactions with UDP/
P2Y6R in the apoptosis of neurons.
We sought to identify the underlying mechanism of
P2Y6R activation in accelerating neuroinflammation.
Previous studies have found that P2Y receptor binding
with the corresponding ligand could regulate activity
through a variety of intracellular signal transduction path-
ways, mainly MAPK signaling pathways [31, 32]. Purine
receptors can also activate many transcription factors,
including NF-κB, NFAT, CREB, and AP-1 [45–47]. We
observed that activation of P2Y6R by UDP could induce
the phosphorylation of ERK1/2 but not p38 or JNK. A
ERK1/2 inhibitor downregulated the expression levels of
MIP-2 and COX-2. A similar phenomenon has been
observed in monocytes [28] and intestinal inflamma-
tion [17]. It was reported that UTP markedly in-
creased the phosphorylation of ERK1/2, p38, and JNK
in cultured spinal microglia [32], while we did not
observe the activation of p38 and JNK, which may be
due to the different agonists and cell lines used.
However, LPS could activate all of the MAPK path-
ways, and this discrepancy suggested that the effect of
LPS on neuroinflammation cannot be solely explained
by the release of UDP and the activation of the
ERK1/2 pathway via P2Y6R. Nonetheless, our results
support a key role of UDP/P2Y6R signaling coupled
with ERK1/2 in stimulating the release of inflamma-
tory cytokines. However, the exact mechanism of
P2Y6R upregulation in PD patients and its activation
in microglia remain largely unknown and warrant
further investigation.
Conclusions
There are two novel aspects of our study: (1) P2Y6R can
be used as a potential clinical biomarker of PD and (2)
microglial P2Y6R is involved in the neuroinflammation
through an autocrine loop based on LPS-triggered UDP
secretion and accelerated neuroinflammatory responses
through the ERK1/2 pathway. These findings suggest
that blocking P2Y6R should be explored as a potential
therapeutic strategy for the treatment of PD patients.
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